Meng-yuan Zhang

138 Xianlin Road
Nanjing, 210023, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Design, synthesis and structure-activity relationship analysis of bufalin as antitumor agents.

Design, synthesis and structure-activity relationship analysis of bufalin as antitumor agents.

Journal: Bioorganic & medicinal chemistry letters

Published: June 09, 2026

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: May 23, 2026

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.

Journal: Journal of medicinal chemistry

Published: May 02, 2026

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: April 03, 2026

Preparation of glycine-pectin complex and its application in drug delivery system.

Preparation of glycine-pectin complex and its application in drug delivery system.

Journal: Natural product research

Published: August 14, 2025

MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.

MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.

Journal: Journal of medicinal chemistry

Published: February 25, 2025

Metabolite Profiling of Danatinib in Mice Using Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry In Vitro and In Vivo.

Metabolite Profiling of Danatinib in Mice Using Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry In Vitro and In Vivo.

Journal: Biomedical chromatography : BMC

Published: September 29, 2024

Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.

Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.

Journal: Journal of medicinal chemistry

Published: September 11, 2024

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Journal: Drug development research

Published: July 24, 2024

Correction to "Discovery of RORγ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging".

Correction to "Discovery of RORγ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging".

Journal: Journal of medicinal chemistry

Published: March 26, 2024

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.

Journal: Journal of medicinal chemistry

Published: March 14, 2024

Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.

Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.

Journal: European journal of medicinal chemistry

Published: March 06, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026